Post-Amgen Patent Playbook: Section 112 Under the Microscope
April 30, 2025
The Supreme Court’s unanimous 2023 decision in Amgen v. Sanofi reshaped enablement analysis for broad genus patent claims. In the wake of Amgen, broad functional claims have been scrutinized rigorously for sufficient disclosure. This article summarizes key post-Amgen decisions, which illustrate how patent drafters and litigators must navigate the fine line between claim breadth and disclosure depth in the post-Amgen era.
Despite Appearances, Crypto Enforcement Still Has a Pulse
April 30, 2025
The contrast between the Trump Administration’s ostentatious embrace of cryptocurrency and the prior administration’s chilly skepticism has led some to suggest that the multi-billion-dollar industry is at the dawn of an enforcement-devoid free for all. A more recent, lower key announcement, however, indicates that enforcement still has a pulse.
Fresh Filings
April 30, 2025
Notable recent court filings in entertainment law.
Gen AI Unlikely to Bring Down Law Firm Rates
April 30, 2025
Clients may hold out hope that the adoption of generative AI tools will bring down the rates they pay outside counsel, but a recent survey suggests they shouldn’t hold their breath.
Players on the Move
April 30, 2025
A look at moves among attorneys, law firms, companies and other players in entertainment law.
Some Signals Appear Trump Administration Will Enforce White-Collar Crime
April 30, 2025
The first months of the Trump administration have undeniably brought change to the white collar enforcement space. On Feb. 10, President Donald Trump issued an executive order directing Attorney General Pam Bondi to pause all existing cases brought under the Foreign Corrupt Practices Act. Since then, the administration has signaled a withdrawal. This change in climate has not gone unnoticed by defense counsel.
IP News
April 30, 2025
Federal Circuit Examines Written Description Requirements for U.S. Patent Application Publications Used as Prior Art Under Pre-AIAFederal Circuit Denies Preliminary Injunction In a Biologics Price Competition and Innovation Act Case